SAB Biotherapeutics

0 followers


SAB Biotherapeutics is advancing a new class of immunotherapies with targeted, fully human polyclonal antibodies for the treatment of Covid-19, diabetes, organ transplant & flu.

Industries

Headquarters

Stage

Employees

Links

Org chart

Eddie J. Sullivan
Co-Founder, President & CEO

Eddie J. Sullivan

Collapse
Christoph Bausch
Chief Science Officer
Russell P. Beyer, MBA, CMA
Chief Financial Officer, EVP
Alexandra Kropotova
EVP, Chief Medical Officer
Melissa Ullerich
Chief Corporate Communications & Investor Relations Officer
Dr. Carlos Carrillo, MS, PhD.
SVP of Regulatory Affairs at SAB Biotherapeutics
Jacob Spade
Senior Director Human Resources
Angela Parizek
Vice President, Clinical Operations